Valuation: Aprogen Biologics Inc.

Market Cap	27B 17.85M 15.66M 14.42M 13.39M 25.35M 1.69B 25.79M 173M 67.26M 836M 66.99M 65.56M 2.9B	P/E 2024	-0.79x	P/E 2025	-0.6x
Enterprise Value	204B 135M 118M 109M 101M 192M 12.81B 195M 1.31B 509M 6.32B 507M 496M 21.94B	EV / Sales 2024	3.66x	EV / Sales 2025	3.82x
Free-Float	95.86%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : Aprogen Biologics Inc.

06-30	Aprogen Biologics Inc. announced that it has received KRW 50.8 billion in funding from APTOCROM Inc.	CI
05-28	Aprogen Biologics Inc. announced that it has received KRW 10 billion in funding from Aprogen, Inc.	CI
05-20	Aprogen Biologics Inc. announced that it expects to receive KRW 10 billion in funding from Aprogen, Inc.	CI
05-14	Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-27	Aprogen Biologics Inc. announced that it has received KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
04-12	Aprogen Biologics Inc. announced that it expects to receive KRW 2.000001375 billion in funding from Aprogen, Inc.	CI
03-20	Aprogen Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-13	Aprogen Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-23	Aprogen Biologics Inc. announced that it has received KRW 15 billion in funding from APTN Inc.	CI
25-10-15	Aprogen Biologics Inc. announced that it expects to receive KRW 15 billion in funding from APTN Inc.	CI
25-08-13	Aprogen Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-21	Aprogen Medicines Inc. agreed to acquire an additional 20.06% stake in AP Healthcare Inc. from Aprogen Biologics Inc. for KRW 58.4 billion.	CI
25-05-14	Aprogen Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

More news

News in other languages: Aprogen Biologics Inc.

20-11-23	MÄRKTE ASIEN/Kräftige Gewinne in Seoul und Schanghai - Tokio pausiert
20-11-23	MÄRKTE ASIEN/Aufwärts mit Impfstoff-Optimismus

More news

Managers and Directors: Aprogen Biologics Inc.

Manager	Title	Age	Since
Jae-Seob Kim CEO	Chief Executive Officer	63	2023-10-12
Jung-Chool Kim CEO	Chief Executive Officer	70	2012-03-31
Jong-Soo Kang SAM	Sales & Marketing	62	-

Director	Title	Age	Since
Jung-Chool Kim BRD	Director/Board Member	70	2012-03-31
Dong-Chul Shin BRD	Director/Board Member	65	2020-03-22
Jae-Seob Kim BRD	Director/Board Member	63	2023-10-12

More insiders

Aprogen Biologics Inc, formerly Aprogen Pharmaceuticals Inc, is a Korea-based company principally engaged in the pharmaceutical business. The Company operates its business through two segments. The Medicine Business segment is engaged in the manufacture and sale of central nervous system drugs, autonomic agents, arteriosclerosis agents, metabolic agents, circulatory system drugs, biopharmaceuticals and others. The Segment is also engaged in the manufacture and sale of cosmetics such as skin moisturizers and others. The Gaming Business segment is engaged in the development and operation of role-playing games (RPGs).

Employees

379

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-07-07	₩2,050.00	-1.20%	119,088
26-07-06	₩2,075.00	-1.43%	41,860
26-07-03	₩2,105.00	+5.25%	48,634
26-07-02	₩2,000.00	-4.08%	59,392
26-07-01	₩2,085.00	+0.97%	87,454

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. Other stock markets 2026-07-07			5-day change	1st Jan Change
2,050.00 ^KRW	-1.20%		-3.30%	-73.67%

1 day	-1.20%
1 week	-3.30%
Current month	-0.73%
1 month	-23.65%
3 months	-46.61%
6 months	-74.26%
Current year	-73.67%

1 week	1,972	2,250
1 month	1,869	2,880
Current year	1,869	8,490
1 year	1,869	10,395
3 years	1,869	108,600
5 years	1,869	204,750
10 years	1,869	1,000,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-06-27	Sung-Ho Kang	Fiscal year	Executive/Senior Manager	6,183	0.0046%
24-06-27	Sung Nao	Fiscal year		11,846	0.0089%
24-06-27	An-soo Kim	Fiscal year		2,625	0.0020%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
APROGEN BIOLOGICS INC.	-1.20%	-3.30%	-79.60%	-96.30%	17.84M
ELI LILLY AND COMPANY	+2.96%	+3.01%	+59.87%	+173.31%	1,070B
JOHNSON & JOHNSON	+3.05%	+5.23%	+72.11%	+67.81%	624B
ABBVIE INC.	-0.04%	+1.20%	+35.72%	+87.93%	450B
ROCHE HOLDING AG	-2.58%	-2.07%	+27.62%	+22.57%	328B
NOVARTIS AG	+1.36%	+0.17%	+29.90%	+49.33%	284B
NOVO NORDISK A/S	+1.98%	+4.08%	-25.78%	-39.02%	217B
AMGEN INC.	+0.45%	+1.65%	+25.65%	+68.35%	198B
GILEAD SCIENCES, INC.	+5.21%	+7.93%	+21.99%	+83.23%	161B
PFIZER INC.	+1.48%	-0.04%	-4.64%	-32.25%	135B
Average	+0.66%	+1.81%	+16.28%	+38.50%	346.75B
Weighted average by Cap.	+0.29%	+2.51%	+41.85%	+87.34%

Aprogen Biologics Inc. Stock

Stocks

A003060

KR7003060001

Pharmaceuticals

Valuation: Aprogen Biologics Inc.

Chart: Aprogen Biologics Inc.

Latest news : Aprogen Biologics Inc.

News in other languages: Aprogen Biologics Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Aprogen Biologics Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

	2024	2025
Net sales	67.38B 44.54M 39.08M 35.98M 33.42M 63.27M 4.23B 64.35M 432M 168M 2.09B 167M 164M 7.24B	73.23B 48.4M 42.47M 39.1M 36.32M 68.76M 4.6B 69.93M 469M 182M 2.27B 182M 178M 7.87B
Net income	-105B -69.39M -60.89M -56.06M -52.07M -98.58M -6.59B -100M -672M -262M -3.25B -260M -255M -11.28B	-170B -113M -98.79M -90.96M -84.48M -160M -10.69B -163M -1.09B -424M -5.27B -423M -414M -18.3B
Net Debt	116B 76.48M 67.11M 61.78M 57.39M 109M 7.26B 110M 741M 288M 3.58B 287M 281M 12.43B	177B 117M 103M 94.6M 87.87M 166M 11.12B 169M 1.13B 441M 5.48B 440M 430M 19.04B